Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.19
NAS:JAZZ's Cash-to-Debt is ranked lower than
94% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:JAZZ: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:JAZZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.63 Max: No Debt
Current: 0.19
Equity-to-Asset 0.46
NAS:JAZZ's Equity-to-Asset is ranked lower than
77% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:JAZZ: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:JAZZ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.84  Med: 0.4 Max: 0.87
Current: 0.46
-0.84
0.87
Debt-to-Equity 0.76
NAS:JAZZ's Debt-to-Equity is ranked lower than
84% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:JAZZ: 0.76 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:JAZZ' s Debt-to-Equity Range Over the Past 10 Years
Min: -64.62  Med: 0.6 Max: 9.37
Current: 0.76
-64.62
9.37
Interest Coverage 8.06
NAS:JAZZ's Interest Coverage is ranked lower than
86% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:JAZZ: 8.06 )
Ranked among companies with meaningful Interest Coverage only.
NAS:JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 9.24 Max: 76.32
Current: 8.06
0.7
76.32
Piotroski F-Score: 6
Altman Z-Score: 3.13
Beneish M-Score: -2.48
WACC vs ROIC
7.91%
14.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 39.12
NAS:JAZZ's Operating Margin % is ranked higher than
95% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:JAZZ: 39.12 )
Ranked among companies with meaningful Operating Margin % only.
NAS:JAZZ' s Operating Margin % Range Over the Past 10 Years
Min: -252.34  Med: 33.51 Max: 46.95
Current: 39.12
-252.34
46.95
Net Margin % 26.18
NAS:JAZZ's Net Margin % is ranked higher than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:JAZZ: 26.18 )
Ranked among companies with meaningful Net Margin % only.
NAS:JAZZ' s Net Margin % Range Over the Past 10 Years
Min: -273.04  Med: 21.83 Max: 49.25
Current: 26.18
-273.04
49.25
ROE % 21.30
NAS:JAZZ's ROE % is ranked higher than
95% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:JAZZ: 21.30 )
Ranked among companies with meaningful ROE % only.
NAS:JAZZ' s ROE % Range Over the Past 10 Years
Min: 4.38  Med: 22.51 Max: 111.92
Current: 21.3
4.38
111.92
ROA % 8.85
NAS:JAZZ's ROA % is ranked higher than
90% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:JAZZ: 8.85 )
Ranked among companies with meaningful ROA % only.
NAS:JAZZ' s ROA % Range Over the Past 10 Years
Min: -113.42  Med: 9.82 Max: 64.21
Current: 8.85
-113.42
64.21
ROC (Joel Greenblatt) % 235.87
NAS:JAZZ's ROC (Joel Greenblatt) % is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:JAZZ: 235.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:JAZZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5278.54  Med: 596.21 Max: 11377.93
Current: 235.87
-5278.54
11377.93
3-Year Revenue Growth Rate 19.30
NAS:JAZZ's 3-Year Revenue Growth Rate is ranked higher than
72% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:JAZZ: 19.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:JAZZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 29.2 Max: 47.7
Current: 19.3
-2.3
47.7
3-Year EBITDA Growth Rate 18.40
NAS:JAZZ's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:JAZZ: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:JAZZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 25.65 Max: 75.7
Current: 18.4
3.8
75.7
3-Year EPS without NRI Growth Rate 22.20
NAS:JAZZ's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:JAZZ: 22.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:JAZZ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.4  Med: 5.4 Max: 61.7
Current: 22.2
-66.4
61.7
GuruFocus has detected 7 Warning Signs with Jazz Pharmaceuticals PLC $NAS:JAZZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:JAZZ's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

JAZZ Guru Trades in Q3 2016

Steven Cohen 352,200 sh (+60.90%)
Joel Greenblatt 153,251 sh (+45.39%)
Pioneer Investments 643,783 sh (+36.37%)
Jim Simons 914,800 sh (+27.14%)
Andreas Halvorsen 737,623 sh (+19.19%)
Lee Ainslie 9,710 sh (+18.27%)
Ken Fisher 2,006 sh (+7.91%)
George Soros Sold Out
Paul Tudor Jones 18,157 sh (-31.61%)
» More
Q4 2016

JAZZ Guru Trades in Q4 2016

Jim Simons 1,560,300 sh (+70.56%)
Pioneer Investments 822,687 sh (+27.79%)
Lee Ainslie 12,240 sh (+26.06%)
Andreas Halvorsen Sold Out
Ken Fisher 1,896 sh (-5.48%)
Steven Cohen 243,100 sh (-30.98%)
Joel Greenblatt 81,417 sh (-46.87%)
Paul Tudor Jones 8,109 sh (-55.34%)
» More
Q1 2017

JAZZ Guru Trades in Q1 2017

Andreas Halvorsen 197,830 sh (New)
Steven Cohen 376,904 sh (+55.04%)
Ken Fisher 1,896 sh (unchged)
Pioneer Investments 708,876 sh (-13.83%)
Lee Ainslie 10,180 sh (-16.83%)
Jim Simons 1,160,963 sh (-25.59%)
Paul Tudor Jones 2,386 sh (-70.58%)
Joel Greenblatt 12,616 sh (-84.50%)
» More
Q2 2017

JAZZ Guru Trades in Q2 2017

Andreas Halvorsen 992,901 sh (+401.90%)
Joel Greenblatt 30,308 sh (+140.23%)
Paul Tudor Jones 4,664 sh (+95.47%)
Lee Ainslie 15,690 sh (+54.13%)
Pioneer Investments 836,427 sh (+17.99%)
Jim Simons 1,201,500 sh (+3.49%)
Ken Fisher 1,896 sh (unchged)
Steven Cohen 32,900 sh (-91.27%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 140.23%0.04%$140.65 - $162.01 $ 151.18-1%30,308
Joel Greenblatt 2017-03-31 Reduce -84.50%0.09%$111.46 - $146.98 $ 151.1816%12,616
Joel Greenblatt 2016-12-31 Reduce -46.87%0.11%$96.74 - $125.35 $ 151.1836%81,417
Ken Fisher 2016-12-31 Reduce -5.48%$96.74 - $125.35 $ 151.1836%1,896
Joel Greenblatt 2016-09-30 Add 45.39%0.07%$118.12 - $152.82 $ 151.1812%153,251
Ken Fisher 2016-09-30 Add 7.91%$118.12 - $152.82 $ 151.1812%2,006
George Soros 2016-09-30 Sold Out 0.03%$118.12 - $152.82 $ 151.1812%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALKS, NAS:PRTA, NAS:AMRN, NAS:AVDL, NAS:NBRV, NAS:NVET, LSE:SHP » details
Traded in other countries:J7Z.Germany,
Headquarter Location:Ireland
Jazz Pharmaceuticals PLC is a biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

Jazz Pharmaceuticals is an Irish-domiciled specialty pharmaceutical firm focused primarily on treatments for orphan indications. Jazz's product portfolio includes Xyrem for narcolepsy and Erwinaze for acute lymphoblastic leukemia.

Top Ranked Articles about Jazz Pharmaceuticals PLC

Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017
Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024
Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024
Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024
Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update
Jazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-M
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017

Ratios

vs
industry
vs
history
PE Ratio 23.10
JAZZ's PE Ratio is ranked higher than
63% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. JAZZ: 23.10 )
Ranked among companies with meaningful PE Ratio only.
JAZZ' s PE Ratio Range Over the Past 10 Years
Min: 10.62  Med: 23.92 Max: 99999999.99
Current: 23.1
10.62
99999999.99
Forward PE Ratio 11.66
JAZZ's Forward PE Ratio is ranked higher than
71% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. JAZZ: 11.66 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.10
JAZZ's PE Ratio without NRI is ranked higher than
64% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. JAZZ: 23.10 )
Ranked among companies with meaningful PE Ratio without NRI only.
JAZZ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.75  Med: 23.83 Max: 99999999.99
Current: 23.1
11.75
99999999.99
Price-to-Owner-Earnings 25.01
JAZZ's Price-to-Owner-Earnings is ranked higher than
61% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. JAZZ: 25.01 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JAZZ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.98  Med: 25.41 Max: 498.21
Current: 25.01
8.98
498.21
PB Ratio 4.14
JAZZ's PB Ratio is ranked lower than
57% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. JAZZ: 4.14 )
Ranked among companies with meaningful PB Ratio only.
JAZZ' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.3 Max: 32
Current: 4.14
2.46
32
PS Ratio 6.05
JAZZ's PS Ratio is ranked higher than
65% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. JAZZ: 6.05 )
Ranked among companies with meaningful PS Ratio only.
JAZZ' s PS Ratio Range Over the Past 10 Years
Min: 0.22  Med: 5.87 Max: 12
Current: 6.05
0.22
12
Price-to-Free-Cash-Flow 15.99
JAZZ's Price-to-Free-Cash-Flow is ranked higher than
60% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. JAZZ: 15.99 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JAZZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.82  Med: 18.06 Max: 91.14
Current: 15.99
11.82
91.14
Price-to-Operating-Cash-Flow 15.15
JAZZ's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. JAZZ: 15.15 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JAZZ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.61  Med: 15.8 Max: 55.81
Current: 15.15
9.61
55.81
EV-to-EBIT 17.28
JAZZ's EV-to-EBIT is ranked higher than
58% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. JAZZ: 17.28 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.5  Med: 16.7 Max: 74.1
Current: 17.28
-8.5
74.1
EV-to-EBITDA 14.46
JAZZ's EV-to-EBITDA is ranked higher than
58% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. JAZZ: 14.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 13.85 Max: 42.2
Current: 14.46
-10.9
42.2
EV-to-Revenue 6.78
JAZZ's EV-to-Revenue is ranked higher than
64% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. JAZZ: 6.78 )
Ranked among companies with meaningful EV-to-Revenue only.
JAZZ' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 6.3 Max: 11.9
Current: 6.78
1.5
11.9
PEG Ratio 0.80
JAZZ's PEG Ratio is ranked higher than
78% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. JAZZ: 0.80 )
Ranked among companies with meaningful PEG Ratio only.
JAZZ' s PEG Ratio Range Over the Past 10 Years
Min: 0.54  Med: 0.82 Max: 8.83
Current: 0.8
0.54
8.83
Shiller PE Ratio 93.95
JAZZ's Shiller PE Ratio is ranked lower than
88% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. JAZZ: 93.95 )
Ranked among companies with meaningful Shiller PE Ratio only.
JAZZ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 88.64  Med: 196.37 Max: 978.38
Current: 93.95
88.64
978.38
Current Ratio 2.65
JAZZ's Current Ratio is ranked lower than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. JAZZ: 2.65 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 2.71 Max: 5.55
Current: 2.65
0.2
5.55
Quick Ratio 2.49
JAZZ's Quick Ratio is ranked lower than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. JAZZ: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.58 Max: 5.46
Current: 2.49
0.17
5.46
Days Inventory 115.67
JAZZ's Days Inventory is ranked higher than
58% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. JAZZ: 115.67 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 95.63 Max: 146.18
Current: 115.67
70.82
146.18
Days Sales Outstanding 56.54
JAZZ's Days Sales Outstanding is ranked higher than
56% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. JAZZ: 56.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.12  Med: 46.7 Max: 58
Current: 56.54
30.12
58
Days Payable 93.22
JAZZ's Days Payable is ranked higher than
71% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. JAZZ: 93.22 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 73.94  Med: 79.92 Max: 150.36
Current: 93.22
73.94
150.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
JAZZ's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. JAZZ: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JAZZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.4  Med: -13.8 Max: -1.1
Current: -1.1
-32.4
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.41
JAZZ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. JAZZ: 1.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JAZZ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.16  Med: 2.8 Max: 77.26
Current: 1.41
1.16
77.26
Price-to-Median-PS-Value 1.03
JAZZ's Price-to-Median-PS-Value is ranked lower than
58% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. JAZZ: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JAZZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 1 Max: 1.56
Current: 1.03
0.05
1.56
Price-to-Peter-Lynch-Fair-Value 0.92
JAZZ's Price-to-Peter-Lynch-Fair-Value is ranked higher than
82% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. JAZZ: 0.92 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JAZZ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.04 Max: 14.94
Current: 0.92
0.67
14.94
Earnings Yield (Greenblatt) % 5.78
JAZZ's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. JAZZ: 5.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JAZZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -175.5  Med: 5.1 Max: 10.7
Current: 5.78
-175.5
10.7
Forward Rate of Return (Yacktman) % 30.45
JAZZ's Forward Rate of Return (Yacktman) % is ranked higher than
80% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. JAZZ: 30.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JAZZ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -43.1  Med: 1.75 Max: 49.5
Current: 30.45
-43.1
49.5

More Statistics

Revenue (TTM) (Mil) $1,541.24
EPS (TTM) $ 6.55
Beta1.34
Short Percentage of Float5.78%
52-Week Range $95.80 - 163.75
Shares Outstanding (Mil)60.06

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,636 1,884 2,155 2,407
EPS ($) 10.72 12.96 15.29 17.57
EPS without NRI ($) 10.72 12.96 15.29 17.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.82%
Dividends per Share ($)
» More Articles for NAS:JAZZ

Headlines

Articles On GuruFocus.com
Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 Sep 12 2017 
Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Op Sep 01 2017 
Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference Aug 30 2017 
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Aug 29 2017 
Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 Aug 18 2017 
Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 Aug 17 2017 
Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update Aug 03 2017 
Jazz Pharmaceuticals Announces FDA Approval of Vyxeos™ (daunorubicin and cytarabine) Liposome for Aug 03 2017 
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology t Jul 26 2017 
Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 Jul 24 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Sep 15 2017
ETFs with exposure to Jazz Pharmaceuticals Plc : September 14, 2017 Sep 14 2017
Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Sep 13 2017
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio Sep 13 2017
Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : September 12, 2017 Sep 12 2017
Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 Sep 12 2017
Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US :... Sep 11 2017
Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17 Sep 11 2017
How Is Jazz’s Defitelio Positioned after 2Q17? Sep 08 2017
This Could Drive Jazz Pharmaceuticals’ Revenue Growth Sep 08 2017
Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018 Sep 08 2017
Behind Jazz’s Strategic Collaboration with ImmunoGen Sep 07 2017
How Did Jazz Pharmaceuticals Perform in 1H17? Sep 07 2017
Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17 Sep 07 2017
5 Key Things You Should Watch With Jazz Pharmaceuticals Sep 07 2017
Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the... Sep 05 2017
Bull of the Day: Jazz Pharmaceuticals (JAZZ) Sep 05 2017
Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers'... Sep 01 2017
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders Sep 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}